Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00165035 · ClinicalTrials.gov registry record · Phase 3
Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)
A Phase 3 study, sponsored by Cordis US.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,701
- Enrollment target
NCT00165035 is a Phase 3 study that has completed, run by Cordis US. The registered enrollment target is 1,701 participants.
The verdict
NCT00165035, a Phase 3 study, has completed, sponsored by Cordis US.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,701 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of the investigational stent CoStar™ Paclitaxel-Eluting Coronary Stent- a reservoir based DES system in comparison to a surface coated DES stent (TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent) in the treatment of single-vessel (one blood vessel) and multi-vessel (two or three blood vessels) coronary artery disease.
Interventions
- DEVICE CoStar Paclitaxel Drug Eluting Coronary Stent System
- DEVICE TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,701 participants |
| Start Date | 2005-05 |
| Est. Completion | 2011-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00165035
The ClinicalTrials.gov registry entry for NCT00165035 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,701 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cordis US, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CoStar Paclitaxel Drug Eluting Coronary Stent System is the first listed.
NCT00165035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00165035 about?
NCT00165035 is a clinical study titled "Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)". The purpose of this study is to evaluate the safety and effectiveness of the investigational stent CoStar™ Paclitaxel-Eluting Coronary Stent- a reservoir based DES system in comparison to a surface coated DES stent (TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent) in the treatment of single-vesse...
What is the current status of trial NCT00165035?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,701 participants. The study started on 2005-05. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00165035?
The interventions under investigation include: CoStar Paclitaxel Drug Eluting Coronary Stent System (DEVICE), TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent (DEVICE).
Who is sponsoring clinical trial NCT00165035?
This trial is sponsored by Cordis US, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.